FDA Confirms Paragraph IV Patent Challenge of Kybella 206333 (Deoxycholic Acid) Injection
The purchase price is $56.50 a share in cash, the companies said Monday in a statement, a 14 percent premium to Pleasanton, California-based Zeltiq’s closing price Friday of $49.40. Through Friday, the stock had already more than doubled in the last 12 months.
Allergan CEO Brent Saunders is tired of hearing from investors that chin-fat buster Kybella’s launch isn’t going as well as, say, that of IBS-D med Viberzi or schizophrenia treatment Vraylar. So in a Monday presentation at the J.P. Morgan Healthcare Conference, he did his best to set the record straight.
Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced it has acquired Creabilis plc, a privately held specialty pharmaceutical company focused on developing first-in-class topical treatments for common inflammatory skin conditions, including psoriasis, atopic dermatitis and pruritus (itch). Under the terms of the agreement, Sienna will make an undisclosed upfront payment in cash and stock, as well as additional payments contingent upon achieving specific regulatory and commercial milestones, which could exceed $150 million in aggregate. Additional terms were not disclosed.
Belkyra is a prescription medicine for the treatment of moderate-to-severe convexity or fullness associated with submental fat (often called double chin) in adults when the presence of submental fat has a psychological impact for the patient. Fullness under the chin can impact how a person feels about themselves and, for both women and men, can lead to feelings of negative self-impressio
Allergan plc (NYSE: AGN) a leading global pharmaceutical company, kicked off their Live Chin Up campaign at an exclusive event at the Frank Gehry-designed IAC Building in New York City today, hosted by television personality and New York Times best-selling author Khloé Kardashian. The Live Chin Up campaign is designed to help encourage people to not let the things that bother them get in their way.
It was a dynamic year for plastic surgery and facial plastic surgeons – and 2015 truly pushed the needle forward on what is possible, even without nips and tucks.
This news may mean the end for the ultimate selfie killer, the double chin. The Food and Drug Administration will now let you say bye-bye to nasty neck fat and hello to a jawline that doesn’t jiggle. The agency approved the first drug that can eliminate neck fat in most people without surgery.
Woe to the person who reaches his 40s and thinks he can keep his chin up, or at the very least, from sagging.
Cosmetic rejuvenation treatments are no longer limited to the face. The next big wave involves treatments for the body — from the first injectable to melt under chin fat, to a new nonsurgical body contouring method that uses ultrasound to trim unwanted inches from the abdomen, midriff and thighs! Check out what Dr. Marina Peredo, a New York dermatologist shared with us.